Form 4: Zimmer Biomet Executive Earns Performance RSUs

Zimmer Biomet's VP, Controller, and CAO, Paul A. Stellato, earned 1,363 performance-based Restricted Stock Units following the 2023-2025 performance period, set to vest on March 6, 2026.

Summary

• Paul A. Stellato, VP, Controller, and CAO of Zimmer Biomet Holdings, Inc. (ZBH), earned 1,363 Restricted Stock Units (RSUs).
• These RSUs were performance-based, originally granted on March 6, 2023, with performance conditions evaluated over the 2023-2025 period.
• The number of earned RSUs was determined on February 19, 2026, based on actual performance.
• The 1,363 earned RSUs are scheduled to vest on March 6, 2026.
• Each RSU represents a contingent right to receive one share of Company common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive, routine disclosure. While it confirms successful executive performance against set targets, it's an expected outcome of a pre-existing compensation plan rather than a new, significant event impacting company fundamentals.

Positives

• Paul A. Stellato successfully met performance conditions for the 2023-2025 period, resulting in the earning of 1,363 Restricted Stock Units.
• The earning of these RSUs aligns executive compensation with company performance, indicating successful achievement of set goals.

Future Outlook

The 1,363 performance-based Restricted Stock Units earned by Paul A. Stellato are scheduled to vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet common stock.

Industry Context

StockSavvy.ai notes that performance-based Restricted Stock Units are a common form of executive compensation, designed to align management incentives with long-term shareholder value creation. The successful earning of these units by a key executive like the VP, Controller, and CAO suggests the company met its internal performance targets for the specified period, which is generally viewed positively within the industry.

Comparison to Industry Standards

• The use of performance-based Restricted Stock Units (RSUs) for executive compensation is a standard practice across the medical device and broader healthcare industry, comparable to compensation structures at companies like Medtronic, Stryker, and Johnson & Johnson.
• The structure, tying RSU vesting to multi-year performance metrics (2023-2025), aligns with best practices for long-term incentive plans aimed at driving sustainable growth and shareholder returns.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting of RSUs, but generally viewed as a positive signal of management achieving performance targets.
• Employees: Reinforces the company's commitment to performance-based incentives and may serve as a positive example of executive goal achievement.

Next Steps

• The 1,363 earned Restricted Stock Units are scheduled to vest on March 6, 2026.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event where performance-based Restricted Stock Units were earned. It reflects the successful achievement of pre-defined performance metrics but does not introduce new information that would fundamentally alter the investment thesis for Zimmer Biomet Holdings, Inc. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Zimmer Biomet, ZBH, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Performance-based compensation